Wall Street Wizardry
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Wall Street Wizardry

Politics

House investigators nix Mueller testimony in Epstein probe over health concerns

by admin August 30, 2025
August 30, 2025
House investigators nix Mueller testimony in Epstein probe over health concerns

House investigators’ plan to grill former FBI Director Robert Mueller has hit a snag. 

The House Oversight Committee was set to have Mueller appear before the panel on Tuesday as part of the House’s probe into Jeffrey Epstein. However, a source familiar with the investigation told Fox News Digital that lawmakers ‘learned that Mr. Mueller has health issues that preclude him from being able to testify.’ 

‘The committee intends to withdraw its subpoena,’ the source said. 

Mueller was one of many notable figures, including the Clintons, who House Oversight Committee Chair James Comer, R-Ky., subpoenaed to testify before the panel. 

He would have been the second witness appearing in-person before the House Oversight Committee after former Attorney General Bill Barr did so last month.

His closed-door deposition was expected to see at least some lawmakers on both sides attend, with the investigation so far seeing wide bipartisan support in an otherwise highly divided era for Congress.

Mueller was most recently in the headlines for his role as special counsel investigating whether Russia interfered in the 2016 election in favor of President Donald Trump.

That probe, which did not find Trump to have committed any wrongdoing, saw 34 people indicted and eight convictions or guilty pleas, including several people associated with the president.

House investigators were expected to dive into Mueller’s time as director of the FBI. He led the bureau under former Presidents George W. Bush and Barack Obama, from September 2001 until September 2013.

It was during that window that the federal government first investigated Epstein, something Comer pointed out in his letter subpoenaing Mueller.

‘When you were FBI Director, an FBI investigation of Mr. Epstein led to an Assistant U.S. Attorney in the Southern District of Florida preparing a draft 60-count indictment of Mr. Epstein in 2007,’ Comer wrote.

‘However, the next year, Mr. Epstein pled guilty in Florida state court to two prostitution offenses, and, in exchange, he and his co-conspirators received immunity from federal prosecution through a non-prosecution agreement.’

That non-prosecution agreement has been widely criticized and is now the basis for Epstein accomplice Ghislaine Maxwell to appeal her conviction and 20-year prison sentence before the Supreme Court.

It’s not clear how much of a role Mueller would have had in that agreement. Alexander Acosta, the former Trump labor secretary and U.S. attorney in Florida who signed off on the deal, is sitting down with the House Oversight Committee for a voluntary transcribed interview later this month.

Comer sent out a flurry of subpoenas last month in relation to the Epstein probe. 

Other figures also compelled to appear after Mueller are former FBI Director James Comey, former Attorney General Loretta Lynch and ex-first couple Bill and Hillary Clinton.

This post appeared first on FOX NEWS

previous post
Legal group sues FDA over puberty blocker records, citing alleged Biden-era cover-up
next post
Spirit Airlines files for Chapter 11 bankruptcy protection for the second time in a year

Related Posts

China’s rare earth tech obsession ensnares US resident...

August 10, 2025

Trump declares US will win global AI race...

July 24, 2025

Lawyer of whistleblower in Trump impeachment case sues...

May 6, 2025

Kash Patel takes reins at scandal-ridden FBI with...

February 22, 2025

America must win the AI race — and...

July 28, 2025

What James Carville doesn’t get about voter priorities

July 25, 2025

Vance visits Capitol Hill to urge senators to...

March 5, 2025

Elon Musk makes surprise appearance at CPAC

February 21, 2025

Fani Willis ordered to pay $54K for violating...

March 18, 2025

Founder of Catholic ministry Word on Fire to...

March 3, 2025

    Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 2

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 3

      Universal’s ‘Wicked: For Good’ creates a unique marketing challenge

      January 26, 2025
    • 4

      US security contractor will take charge of key checkpoint in Gaza as Israeli forces withdraw

      January 25, 2025
    • 5

      Trump re-designates Iranian-backed Houthis as terrorists: ‘Threaten[s] security of American civilians’

      January 23, 2025
    • 6

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 7

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: wallstreetwizardry.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 wallstreetwizardry.com | All Rights Reserved